803 related articles for article (PubMed ID: 15565596)
1. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
2. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
3. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
4. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
[TBL] [Abstract][Full Text] [Related]
5. Radical surgery does not recover immunodeficiency associated with gastric cancer.
Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
[TBL] [Abstract][Full Text] [Related]
6. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study.
Franciosi CM; Piacentini MG; Conti M; Romano F; Musco F; Caprotti R; Rovelli F; Uggeri F
Hepatogastroenterology; 2003; 50(49):297-300. PubMed ID: 12630045
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
10. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
Caprotti R; Brivio F; Fumagalli L; Nobili C; Degrate L; Lissoni P; Parolini D; Messina G; Colciago M; Scotti M; Uggeri F
Anticancer Res; 2008; 28(3B):1951-4. PubMed ID: 18630487
[TBL] [Abstract][Full Text] [Related]
11. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
[TBL] [Abstract][Full Text] [Related]
12. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytic subpopulation changes after open and laparoscopic cholecystectomy: a prospective and comparative study on 38 patients.
Cristaldi M; Rovati M; Elli M; Gerlinzani S; Lesma A; Balzarotti L; Taschieri AM
Surg Laparosc Endosc; 1997 Jun; 7(3):255-61. PubMed ID: 9194291
[TBL] [Abstract][Full Text] [Related]
14. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
[TBL] [Abstract][Full Text] [Related]
16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
[TBL] [Abstract][Full Text] [Related]
18. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood.
Sun CF; Hsieh YY; Ngan KW; Wang WT
Ann Clin Lab Sci; 2001 Apr; 31(2):171-8. PubMed ID: 11337907
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
Brivio F; Lissoni P; Perego MS; Lissoni A; Fumagalli L
J Biol Regul Homeost Agents; 2001; 15(4):370-4. PubMed ID: 11860226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
